Overview

A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a

Status:
Withdrawn
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
Phase IV, proof-of-concept, randomized, open-label, multi-center, two-arm, 9-month study to evaluate the neuroprotective effects of Natalizumab (TYSABRI®) or Interferon beta-1a (AVONEX®) treatments initiated at the time of acute optic neuritis (AON) as measured by RNFL thickness from Optical Coherence Tomography in patients with Relapsing Remitting Multiple Sclerosis (RRMS).
Phase:
Phase 4
Details
Lead Sponsor:
Biogen
Treatments:
Interferon beta-1a
Interferon-beta
Interferons
Natalizumab